Market Overview
The global amyotrophic lateral sclerosis treatment market size was valued at USD 762.79 Million in 2024 and is anticipated to grow from USD 813.89 Million in 2025 to reach USD 1367.36 Million by 2033, exhibiting a CAGR of 6.7% during the forecast period (2025–2033).
The global Amyotrophic Lateral Sclerosis Treatment market...
Market Overview
The global dementia drugs market size was valued at USD 16.86 billion in 2024 and is projected to reach from USD 18.2 billion in 2025 to USD 33.56 billion by 2033, growing at a CAGR of 7.95% during the forecast period (2025-2033).
The global Dementia Drugs market continues to evolve rapidly, driven by shifting consumer trends, rising...
The pharmaceutical industry is constantly looking for ways to make drug development faster, safer, and more efficient. Traditional clinical trials remain a critical step, but they often require significant time and financial investment. Real-world evidence is helping address these challenges by providing additional data that supports decision-making throughout the drug lifecycle. This trend is...
The failure of early-generation neuroprotective drugs, which often targeted single pathways like the NMDA receptor, highlighted a fundamental truth: neurodegeneration is a complex, multi-mechanistic process. This realization has redirected research toward core, pervasive mechanisms of neuronal injury, chiefly chronic neuroinflammation and oxidative stress. Microglial activation, the brain's...
The Lurbinectedin Market has emerged as a notable niche within the oncology therapeutics landscape, driven by advancements in targeted cancer treatments and rising incidence of small cell lung cancer (SCLC) and select solid tumors. The lurbinectedin market is expected to witness market growth at a rate of 45.30% in the forecast period of 2022 to...
Monoclonal Antibodies (mAbs) targeting the CD47 protein are currently the most advanced and widely studied class of agents in the CD47 Targeting Therapeutics domain. Their established history in oncology, high specificity for the target protein, and potential for potent macrophage activation make them the preferred modality for initial drug development.
These antibodies function primarily by...
NAFLD Diagnostics Advancements Revolutionizing Fibrosis Staging Solutions 2026
The Pivot Away from Invasive Procedures
For decades, the standard for assessing the severity and progression of non-alcoholic fatty liver disease, particularly the transition to Non-Alcoholic Steatohepatitis (NASH) and subsequent fibrosis, has relied heavily on the liver biopsy. This invasive procedure carries...
Parkinson’s disease (PD), a chronic neurodegenerative disorder affecting movement, impacts millions globally with symptoms ranging from tremors and rigidity to non-motor challenges like sleep disruptions and cognitive changes. With the Parkinson’s Foundation estimating over 10 million people live with PD worldwide, the demand for effective treatments continues to rise. Traditional...
Global peripheral neuropathy disease burden — affecting approximately twenty million Americans and proportionally significant populations globally, with diabetic neuropathy's prevalence directly tracking the diabetes epidemic — creates enormous and growing treatment demand, with the Peripheral Neuropathy Market reflecting the epidemiological drivers of market growth across...
Schizophrenia Treatment Advancements 2024 New Medications and Therapeutic Breakthroughs
Challenges in Current Treatment Regimens
Schizophrenia, affecting approximately 1% of the global population, impacts millions with symptoms ranging from hallucinations to cognitive impairments. Traditional antipsychotic medications, while effective for many, often come with side effects like weight gain,...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
thai 
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china